VIA Thaw™ preview
Asymptote are excited to reveal a preview of the upcoming automated thawing systems for cryobags and cryovials, developed in partnership with The Cell and Gene Therapy Catapult
A cryogenic cold chain enables the most cost effective route for manufacture and distribution of CBTs. The cryochain requires controlled-rate freezing, cryogenic storage and controlled thawing under Good Manufacturing Practice (GMP) conditions. There is currently no commercially available equipment for validated thawing of cryopreserved cellular products at the point of delivery. Asymptote partnered with the Cell and Gene Therapy Catapult to develop a family of controlled thawing devices that would address this gap.
The Cell Therapy Catapult and Asymptote, a leading specialist in cryopreservation, based in Cambridge, UK, are combining forces to advance the development of a novel point-of-care Thawing System for Cell-Based Therapies.
This device is intended to solve a global barrier to commercialisation of cell therapies, by simplifying the delivery of these therapies to patients by addressing significant challenges of delivery at the point-of-care.
Read full article
All our thawers work without using water or any other fluid, they are all fully automated and tightly control the thawing process. Every unit synchronizes thawing programs and data logs from each thaw to a centralized platform accessible from a web browser or mobile device.
To find out more or to register for our early access programme, please contact us.